BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37068931)

  • 1. Disability accrual in primary and secondary progressive multiple sclerosis.
    Harding-Forrester S; Roos I; Nguyen AL; Malpas CB; Diouf I; Moradi N; Sharmin S; Izquierdo G; Eichau S; Patti F; Horakova D; Kubala Havrdova E; Prat A; Girard M; Duquette P; Grand'Maison F; Onofrj M; Lugaresi A; Grammond P; Ozakbas S; Amato MP; Gerlach O; Sola P; Ferraro D; Buzzard K; Skibina O; Lechner-Scott J; Alroughani R; Boz C; Van Pesch V; Cartechini E; Terzi M; Maimone D; Ramo-Tello C; Yamout B; Khoury SJ; La Spitaleri D; Sa MJ; Blanco Y; Granella F; Slee M; Butler E; Sidhom Y; Gouider R; Bergamaschi R; Karabudak R; Ampapa R; Sánchez-Menoyo JL; Prevost J; Castillo-Trivino T; McCombe PA; Macdonell R; Laureys G; Van Hijfte L; Oh J; Altintas A; de Gans K; Turkoglu R; van der Walt A; Butzkueven H; Vucic S; Barnett M; Cristiano E; Hodgkinson S; Iuliano G; Kappos L; Kuhle J; Shaygannejad V; Soysal A; Weinstock-Guttman B; Van Wijmeersch B; Kalincik T;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):707-717. PubMed ID: 37068931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
    Signori A; Lorscheider J; Vukusic S; Trojano M; Iaffaldano P; Hillert J; Hyde R; Pellegrini F; Magyari M; Koch-Henriksen N; Sørensen PS; Spelman T; van der Walt A; Horakova D; Havrdova E; Girard M; Eichau S; Grand'Maison F; Gerlach O; Terzi M; Ozakbas S; Skibina O; Van Pesch V; Sa MJ; Prevost J; Alroughani R; McCombe PA; Gouider R; Mrabet S; Castillo-Trivino T; Zhu C; de Gans K; Sánchez-Menoyo JL; Yamout B; Khoury S; Sormani MP; Kalincik T; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):23-30. PubMed ID: 36171104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.
    Tremlett H; Zhao Y; Devonshire V;
    J Neurol; 2009 Mar; 256(3):374-81. PubMed ID: 19308306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of disease progression in a cohort of Tunisian progressive Multiple Sclerosis.
    Souissi A; Mrabet S; Nasri A; Ben Djebara M; Gargouri A; Kacem I; Gouider R
    Mult Scler Relat Disord; 2021 Nov; 56():103232. PubMed ID: 34619488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of secondary progressive multiple sclerosis after early worsening of disability.
    Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials.
    Orbach R; Zhao Z; Wang YC; O'Neill G; Cadavid D
    PLoS One; 2012; 7(10):e45409. PubMed ID: 23049678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
    Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH
    Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rehabilitation with neuromuscular electrical stimulation leads to functional gains in ambulation in patients with secondary progressive and primary progressive multiple sclerosis: a case series report.
    Wahls TL; Reese D; Kaplan D; Darling WG
    J Altern Complement Med; 2010 Dec; 16(12):1343-9. PubMed ID: 21138391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
    Lorscheider J; Kuhle J; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Hupperts R; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Trojano M; Ramo-Tello C; Lechner-Scott J; Pucci E; Solaro C; Slee M; Van Pesch V; Sanchez Menoyo JL; van der Walt A; Butzkueven H; Kappos L; Kalincik T;
    Eur J Neurol; 2019 Feb; 26(2):363-370. PubMed ID: 30298572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study.
    Cortesi PA; Fornari C; Capra R; Cozzolino P; Patti F; Mantovani LG
    Value Health; 2022 Sep; 25(9):1489-1498. PubMed ID: 35484029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T;
    Neurology; 2017 Sep; 89(10):1050-1059. PubMed ID: 28794248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.